191 related articles for article (PubMed ID: 9770112)
1. PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance.
Atadja P; Watanabe T; Xu H; Cohen D
Cancer Metastasis Rev; 1998 Jun; 17(2):163-8. PubMed ID: 9770112
[TBL] [Abstract][Full Text] [Related]
2. Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.
Uchiyama-Kokubu N; Watanabe T; Cohen D
Jpn J Cancer Res; 2001 Oct; 92(10):1116-26. PubMed ID: 11676863
[TBL] [Abstract][Full Text] [Related]
3. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
4. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
5. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein.
Goulding CW; Giuliano AE; Cabot MC
Cancer Lett; 2000 Feb; 149(1-2):143-51. PubMed ID: 10737718
[TBL] [Abstract][Full Text] [Related]
6. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
7. A bioassay for the activity of PSC 833 in human serum for modulation of P-glycoprotein-mediated multidrug resistance.
Uchiyama-Kokubu N; Watanabe T; Nakajima M
Anticancer Drugs; 2000 Aug; 11(7):583-90. PubMed ID: 11036963
[TBL] [Abstract][Full Text] [Related]
8. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells.
Lacayo NJ; Duran GE; Sikic BI
J Exp Ther Oncol; 2003; 3(3):127-35. PubMed ID: 14641819
[TBL] [Abstract][Full Text] [Related]
9. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models.
Watanabe T; Nakayama Y; Naito M; Oh-hara T; Itoh Y; Tsuruo T
Anticancer Drugs; 1996 Nov; 7(8):825-32. PubMed ID: 8991185
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic approaches to reversing multidrug resistance.
Sikic BI
Semin Hematol; 1997 Oct; 34(4 Suppl 5):40-7. PubMed ID: 9408960
[TBL] [Abstract][Full Text] [Related]
11. Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models.
Watanabe T; Naito M; Oh-hara T; Itoh Y; Cohen D; Tsuruo T
Jpn J Cancer Res; 1996 Feb; 87(2):184-93. PubMed ID: 8609068
[TBL] [Abstract][Full Text] [Related]
12. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.
Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.
Zacherl J; Hamilton G; Thalhammer T; Riegler M; Cosentini EP; Ellinger A; Bischof G; Schweitzer M; Teleky B; Koperna T
Cancer Chemother Pharmacol; 1994; 34(2):125-32. PubMed ID: 7910786
[TBL] [Abstract][Full Text] [Related]
15. [SDZ PSC 833: a novel modulator of MDR].
Covelli A
Tumori; 1997; 83(5 Suppl):S21-4. PubMed ID: 9446255
[TBL] [Abstract][Full Text] [Related]
16. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S20-4. PubMed ID: 9272129
[TBL] [Abstract][Full Text] [Related]
17. Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment.
Jetté L; Murphy GF; Béliveau R
Int J Cancer; 1998 May; 76(5):729-37. PubMed ID: 9610733
[TBL] [Abstract][Full Text] [Related]
18. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
[TBL] [Abstract][Full Text] [Related]
19. Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008.
Lee BD; French KJ; Zhuang Y; Smith CD
Oncol Res; 2003; 14(1):49-60. PubMed ID: 14552591
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P-glycoprotein.
Horton JK; Thimmaiah KN; Altenberg GA; Castro AF; Germain GS; Gowda GK; Houghton PJ
Mol Pharmacol; 1997 Dec; 52(6):948-57. PubMed ID: 9415704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
